Skyran Biologics has a group of compounds that treat many of the major eye diseases
These compounds are at different stages of development
– with some ready for manufacture
The market for these compounds is huge – and growing
With appropriate investment Skyran Biologics will be generating revenue in 1-2 years
With new drugs coming on line we expect continuing robust revenue growth.